Sirolimus by OrphAI Therapeutics for Bronchiolitis Obliterans: Likelihood of Approval

Sirolimus is under clinical development by OrphAI Therapeutics and currently in Phase II for Bronchiolitis Obliterans.

Medi-Cal’s fragmented system can make moving a nightmare

When Lloyd Tennison moved from Walnut Creek to Stockton last year, he assumed his coverage under Medi-Cal, California’s safety-net health insurance program, would be transferred

July 7, 2023

Exploring the protective effects of HSD17B13 in hepatic steatosis

Chronic liver disease (CLD) is a growing global health challenge, accounting for millions of deaths each year. Its major contributors include metabolic dysfunction-associated steatohepatitis (MASH),

November 9, 2024

Abeona’s new Form 483 is another manufacturing setback for its rare skin condition asset

Abeona Therapeutics was handed a Form 483 “related to process controls” for its epidermolysis bullosa candidate in a second manufacturing-related roadblock for the program, with

March 19, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.